Gold sell-off did not derail Deutsche Bank's bullish $6,000 target
proactiveinvestors.co.uk
Want to monitor INAB?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor INABin8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.